Previous Close | 5.70 |
Open | N/A |
Bid | 9.70 |
Ask | 13.00 |
Strike | 40.00 |
Expire Date | 2024-05-17 |
Day's Range | 5.70 - 5.70 |
Contract Range | N/A |
Volume | |
Open Interest | N/A |
Despite Challenges, Company Shows Promising Growth in Key Areas
Supernus Pharmaceuticals ( NASDAQ:SUPN ) First Quarter 2024 Results Key Financial Results Revenue: US$143.6m (down 6.6...
ROCKVILLE, Md., May 09, 2024 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that the Company will hold a webcast and conference call on Thursday, May 23, 2024, at 4:30 p.m. ET to review interim data from the open-label Phase IIa study of SPN-817 for treatment-resistant seizures. A live webcast with presentation slides will